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Multiple myeloma (MM) is considered an incurable B cell malignancy, although many patients can beneﬁt
from high-dose therapy with autologous stem cell transplantation (ASCT) as a ﬁrst-line treatment. In non-
Hodgkin lymphoma (NHL), ASCT is usually performed after relapse with curative intent. Disease progres-
sion is often associated with increased angiogenesis, in which endothelial progenitor cells (EPC) may have a
central role. Here, we investigated the clinical impact of EPC levels in peripheral blood stem cell (PBSC)
autografts for MM and NHL patients who received ASCT. EPC were identiﬁed by ﬂow cytometry as aldehyde
dehydrogenasehi CD34þ vascular endothelial growth factor receptor 2þ CD133þ cells in both MM and NHL
autografts. In MM, there was a positive correlation between EPC percentage and serum (s)-b2-microglobulin
levels (r2 ¼ .371, P ¼ .002). Unlike for NHL patients, MM patients with high numbers of infused EPC (EPC cells
per kilogram) during ASCT had signiﬁcant shorter progression-free survival (PFS) (P ¼ .035), overall survival
(P ¼ .044) and time to next treatment (P ¼ .009). In multivariate analysis, EPC cells per kilogram was a sig-
niﬁcant independent negative prognostic indicator of PFS (P ¼ .03). In conclusion, the presence of high
number of EPC in PBSC grafts is associated with adverse prognosis after ASCT in MM.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Multiple myeloma (MM) is a malignant disorder charac-
terized by clonal expansion of postgerminal-center malig-
nant B cells in the bone marrow [1-3]. High-dose
chemotherapy followed by autologous stem cell trans-
plantation (ASCT) is considered the standard ﬁrst-line ther-
apy for patients <65 years of age [4]. Survival ranges from a
few months to more than 20 years, and several prognostic
indicators have been established. Median progression-free
survival (PFS) for patients who achieve a complete
response (CR) after ASCT is signiﬁcantly longer comparededgments on page 846.
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ty for Blood and Marrow Transplantation.with non-CR patients [5]. Moreover, high-risk patients with
t(4;14) or del(17p) have a poor prognosis after ASCT [6-9].
These patients may actually achieve CR, although at a lower
rate, but early relapses are more common [6]. For stratiﬁca-
tion of MM patients at time of diagnosis, the International
Staging System (ISS) is a simple and reliable tool that
includes b2-microglobulin and albumin [10]. Prognostic in-
dicators and biomarkers are useful and have additive value
when they also give insight into biological mechanisms.
Disease progression in MM is accompanied by an increase
of bone marrow angiogenesis [11,12]. High level of vascular
endothelial growth factor (VEGF) levels in peripheral blood
from MM patients has been reported to be associated with
more advanced disease, and levels of VEGF in bone marrow
specimens correlate with b2-microglobulin levels [13].
Myeloma cells have no or only weak expression of VEGF
receptor (VEGFR) 1 and 2. However, VEGF-A stimulation of
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to increase secretion of IL-6, a potent growth and survival
factor for myeloma cells [14]. Accordingly, high levels of IL-6
are associated with adverse prognosis in MM [15].
Endothelial progenitor cells (EPC) were ﬁrst characterized
by Asahara in 1997 based on coexpression of the surface
markers VEGFR2 and CD34 [16]. Later studies have
conﬁrmed that EPC express CD34 [17,18], VEGFR2 [18-20],
and also CD133 [18,19,21]. Primitive hematopoietic progen-
itor cells from bone marrow and umbilical cord blood ex-
press high levels of cytoplasmic aldehyde dehydrogenase
(ALDH) as compared to lymphocytes and monocytes [22].
Furthermore, a ﬂuorescent substrate of ALDH (Aldeﬂuor,
Stem Cell Technologies, Manchester, United Kingdom) can be
used to identify cells with increased ALDH activity [23].
Hence, an interesting strategy would be to identify EPC ac-
cording to a conserved stem cell function (ALDHhi) combined
with phenotypic markers.
Based on previous studies documenting the importance
of angiogenesis in MM, we hypothesized that levels of
EPC in stem cell grafts would be associated with clinical
outcome after ASCT. The aim of the present study was
to explore this by investigating the presence of
ALDHhiCD34þVEGFR2þCD133þ EPC by ﬂow cytometry
technology in autologous peripheral blood stem cell
(PBSC) grafts from patients with MM and from patients
with non-Hodgkin lymphoma (NHL) as a comparison.
MATERIAL AND METHODS
Patients
Forty-one patients (MM; n ¼ 24, NHL; n ¼ 17) with available cry-
opreserved PBSC autograft samples collected in the period between 1995
and 2006 were included in this study. MM patients received induction
therapy with either vincristine 1.6 mg/m2, doxorubicin 36 mg/m2, and
dexamethasone 40 mg (VAD) or cyclophosphamide 1000 mg/m2 and
dexamethasone 40 mg (Cy-Dex) as previously described [24]. PBSC harvest
was performed after 1 cycle of cyclophosphamide (2 g/m2) followed by ﬁl-
grastim. MM patients received melphalan (200 mg/m2) conditioning before
transplantation [24]. NHL induction therapy and mobilization of PBSC are
described in Supplemental Materials. The study was approved by Regional
Committee for Medical Research Ethics (REK-Nord 2011/724).
PBSC Collection and Cryopreservation
PBSC were collected on a Cobe Spectra Apheresis Instrument (Cobe
Laboratories, Gloucester, UK). Cells were subsequently treated to a con-
centration of 100 to 200  106/mL and mixed with dimethyl sulfoxide
(DMSO) to a ﬁnal concentration of 10% DMSO before freezing in the gas
phase of liquid nitrogen. Small aliquots of 1 mL PBSC from all patients were
used in this study.
Reagents and Antibodies
Quantiﬁcation of EPC
Human IgG, reagent grade I4506 was from Sigma-Aldrich (Saint Louis,
MO). Aldeﬂuor was from StemCell Technologies. Antihuman VEGFR2-PE
(clone 89106) was from R&D (Abingdon, United Kingdom). Antihuman
CD34-PE-Cy7 (clone 8G12) was from BD Biosciences (San Jose, CA), anti-
human CD133-APC (clone AC133) was fromMiltenyi Biotec (Lund, Sweden).
Viability analysis
Antihuman CD34-PE (clone 8G12) and via-probe (7AAD) was from BD
Biosciences and antihuman CD45 FITC (clone T29/33) was from Dako
(Glostrup, Denmark).
Quantiﬁcation of clonal circulating plasma cells
Antihuman CD19-PE-Cy7 (clone J3-119) and antihuman CD38-APC
Alexa750 (clone LS198-4-3) was from Beckman Coulter (Brea, CA). Anti-
human CD20-Horizon V-450 (clone L27) and antihuman CD45-Horizon V-
500 (clone 2D1) was from BD Biosciences. Antihuman CD138-APC (clone
MI15), Kappa Light Chains-FITC, and Lambda Light Chains-PE (code number
FR481) were from Dako. CellFIX (catalog number 340181) was from BD
Biosciences. Permeabilization Medium (catalog number GAS002S-100) was
from Life Technology (Thermo Fisher Scientiﬁc, MA).Analysis of EPC and Clonal Circulating Plasma Cells in Stem Cell Grafts
by Flow Cytometry
Cryopreserved PBSCwere thawed, washed in PBSwith .2% bovine serum
albumin (PBSA), and counted. To block Fc receptor binding, 5  106 cells
were incubated with 5 mg human IgG in 15 minutes at 4C. Cells were then
washed, 400 mL Aldeﬂuor assay buffer was added, and cells were incubated
with 5 mL/.61mg Aldeﬂuor for 30 minutes at 37C. Dieth-
ylaminobenzaldehyde, a speciﬁc ALDH inhibitor, was used as a negative
control, as previously described [25]. Cells were then washed, and 200 ml
Aldeﬂuor Assay Buffer was added. Then, cells were costained with 10 mL
anti-VEGFR2-PE, 2.5 mL anti-CD34-PE-Cy7, and 10 mL anti-CD133-APC for 30
minutes at 4C. In a separate tube, 3  106 cells in .2% PBSA were incubated
with 5 mL anti-CD45-FITC, 10 mL anti-CD34-PE, and 20 mL 7AAD. The cells
were then washed, resuspended in Aldeﬂuor assay buffer or PBS, respec-
tively, and stored on ice protected from light until they were collected on a
FACSCanto ﬂow cytometer (Becton Dickinson, Franklin Lakes, NJ). For
quantiﬁcation of clonal circulating plasma cells (cPC), 5  106 cells were
incubated with 2.5 mL CD19-PE-Cy7, 2.5 mL CD20-Horizon V450, 5 mL CD38
APC-Alexa 700, 2.5 mL CD45-Horizon V500, and 10 mL CD138-APC for 20
minutes, dark in room temperature. The cells were then ﬁxated, washed,
and resuspended before incubated with 10 mL kappa/lambda-FITC/PE and
100 mL permeabilizationmedium for 15minutes, dark, in room temperature.
The cells werewashed, resuspended in PBSA, and collected on a FACSCanto II
ﬂow cytometer (Becton Dickinson). Flow cytometry data were analyzed
using FlowJo v7.6.5 (TreeStar, Inc., Ashland, OR).
Statistics, Deﬁnitions, and Endpoints
GraphPad Software (La Jolla, CA) was used to determine statistical sig-
niﬁcance of difference between groups by applying unpaired t-test orMann-
Whitney test as described in ﬁgure legends. Survival curves were plotted
using Kaplan-Meyer method and comparisons were based on log-rank test
with a signiﬁcance level of P < .05. For multivariate analyses, a Cox pro-
portional hazards model was performed with SPSS version 21 (IBM Corpo-
ration, NY). EPC percentage was deﬁned as percentage of VEGFR2þCD133þ
cells in the CD34þ population. EPC cells per kilogramwas deﬁned as a ratio of
EPC (percent of CD34þ population) as determined by ﬂow cytometry mea-
surements, divided by number of stem cells infused during ASCT (CD34þ
cells  106/kg). PFS was measured from PBSC collection to date of pro-
gression or death. Patients who had not progressed or relapsed were
censored on the last date they were known to be alive. Overall survival (OS)
was calculated from PBSC collection to date of death or last visit. Time to next
treatment (TNT) was deﬁned as the time from collection of PBSC to the onset
of new chemotherapy or radiation therapy after ASCT [26]. Disease pro-
gression was deﬁned according to International Myeloma Working Group
Response Criteria [27]. Data on immunoﬁxation was not available. Hence,
near CRwas deﬁned as absence of detectable monoclonal component in the
blood and urine electrophoresis and <5% plasma cells in bone marrow. Very
good partial response was deﬁned as a 90% or more decrease in the serum
monoclonal component level (or urine monoclonal component lower than
100 mg/24 hours in Bence-Jones MM). Partial responsewas deﬁned as a 50%
to 89% decrease in the serummonoclonal component level or a 90% or more
decrease in urine monoclonal component [28,29].
RESULTS
Patient Characteristics
In this study, we included PBSC autograft samples from 24
MM patients and 17 NHL patients. The median age for the
MM cohort at ASCT was 55.3 years, and median observation
time after ASCT was 10.2 years. The MM patients’ charac-
teristics at onset of therapy are presented in more detail in
Table 1. The NHL patients’ characteristics at onset of therapy
are summarized in Supplemental Table S1 and Supplemental
Materials.
Identiﬁcation of CD34þVEGFR2þCD133þ EPC Population
with High ALDH Activity in PBSC Grafts from NHL and
MM Patients
We aimed to characterize the frequencies of EPC in PBSC
autograft samples from NHL and MM patients by stem or
progenitor cell properties as determined by high activity of
intracellular ALDH, combined with surface expression of
CD34, VEGFR2, and CD133. The gating strategy is outlined in
Figure 1A. The cells with high ALDH activity accounted for an
average 4.33% and 3.06% in NHL and MM patient samples,
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ALDHhi population were CD34þ (Figure 1A). Furthermore,
back-gating analysis showed that the majority of
VEGFR2þCD133þ in the autografts also were CD34þALDHhi
(Figure 1B).
The median percentage of 7AADneg cells within an intact
cell gate was 83.2%, thus showing that the quality of the
patient samples was good. For all samples, only cells within
the live cell gate were included in the analysis. Within this
live cell gate, consisting of lymphocytes and monocytes, the
median percentage of CD45þCD34þ7AADneg cells was 93.5%
and, hence, limiting the issue of dead cells confounding the
results.
We found that CD34þVEGFR2þCD133þALDHhi EPC were
present in stem cell grafts from both NHL and MM patients,
but at highly variable frequencies, ranging from .02% to 7.56%
of CD34þ cells (Figure 1C). When comparing NHL and MM,
our analysis did not reveal any signiﬁcant differences in the
percentage ALDHhi cells, CD34þ cells  106/kg, EPC per-
centage, or EPC cells per kilogram (data not shown). MM
patients had no difference in OS, PFS, or TNT according to the
induction chemotherapy (VAD versus Cy-Dex). Furthermore,
no signiﬁcant difference in the EPC percentage within the
MM cohort according to induction chemotherapy before
ASCT (VAD versus Cy-Dex) was found (data not shown).
Thus, variations in percentage of EPCs could not be explained
by diagnosis or type of chemotherapy treatment in this
cohort.
Number of EPC Reinfused during ASCT Predicted Adverse
Outcome in MM Patients
We observed that both MM and NHL patients had highly
variable frequencies of EPC in PBSC grafts (Figure 1C) and we
went on to analyze if levels of EPC were associated with
clinical outcomes. Clinical and ﬂow cytometry data fromMM
patients with percentage of EPC higher or lower than the
cohort median are presented in Table 2. Survival analysis
showed that MM patients with EPC percentage higher thanTable 1
MM Patient Characteristics at Onset of Therapy
ID Sex Age PC, % s-IgA, g/L s-IgG, g/L s-b2-M, mg/L s-Alb
3 M 59 41 .2 42.4 9.80 35.8
4 M 56 10 .9 41.8 1.60 36.2
5 M 52 23 32.5 1.7 2.40 45.8
6 M 56 34 .9 38.6 1.50 33.4
7 F 53 71 33.5 4.3 17.60 30.2
8 M 60 13 .5 3.1 3.40 42.1
10 M 50 46 .1 85.5 5.30 34.6
12 F 63 19 .2 21.9 2.00 40.7
17 F 58 20 .6 9.1 7.28 46.2
20 F 65 22 .2 85.6 4.97 29.3
23 F 48 38 .2 48.6 3.39 31
25 F 59 - .8 10.3 1.47 42.1
26 F 54 68 33.7 3.0 1.95 41.4
28 M 60 15 .4 28.7 1.19 41.6
32 M 41 20 .7 69.8 2.61 35.3
36 F 57 28 .1 105.0 - 22.8
41 M 54 38 .9 9.4 9.31 45.1
42 M 56 7 .4 5.3 1.85 47.7
46 M 49 70 .0 1.7 1.98 44.8
47 M 50 70 .4 106.7 3.84 22.5
48 M 55 1 1.0 13.3 9.60 33.7
49 M 53 72 .1 72.1 5.06 29
52 F 49 1 1.2 9.4 1.20 39.8
54 M 56 20 15.4 6.0 1.50 40.2
ID indicates patient identity number; PC, plasma cells in bone marrow; s-b2-M, s
s-Hb, s-hemoglobin; M, male; F, female.cohort median had signiﬁcant shorter TNT (P ¼ .023) but not
PFS or OS (Supplemental Figure 1A). In contrast, no trend
towards adverse clinical outcome for NHL patients with high
EPC percentage in PBSC grafts was observed (not shown).
We then hypothesized that the actual amount of EPC per
kilogram infused during ASCT, termed EPC cells per kilogram,
might be an even stronger predictor for outcome than per-
centage EPC in the MM cohort. EPC cells per kilogram ranged
from .02 to 2.37, with a median of .24 (Figure 2A). Survival
analysis showed that MM patients with higher than cohort
median EPC cells per kilogram had shorter PFS (P ¼ .035)
(Figure 2B) and OS (P ¼ .044) (Figure 2C), and also signiﬁcant
shorter TNT (P ¼ .009) (Supplemental Figure 1B).
In MM, EPC cells per kilogram was a signiﬁcant inde-
pendent negative prognostic indicator for PFS by multivar-
iate analyses (hazard ratio, 3.44; P ¼ .03) (Table 3). Only
variables with signiﬁcant P values from univariate analyses
were entered into the multivariate analysis, using the Cox
proportional hazards model (backward stepwise, probability
for stepwise entry and removal was set at .05 and .10). P
values < .05 were considered statistically signiﬁcant.
In conclusion, a high number of EPC infused (EPC cells per
kilogram) during ASCT was found to be a negative prognostic
factor for PFS, OS, and TNT in MM patients.
EPC Level in Stem Cell Grafts was Associated with
Increased Pre-treatment s-b2-microglobulin but not ISS
Score in the MM Cohort
We found a signiﬁcant positive correlation between EPC
percentage in PBSC grafts and the level of s-b2-microglobulin
at baseline (Figure 3) (r2 ¼ .371, P ¼ .002). In contrast, there
were no associations between EPC percentage and the levels
of s-albumin or s-LD (elevated versus normal) (data not
shown). We found no associations between high numbers of
EPC and the percentage of plasma cells in bone marrow at
time of diagnosis or before ASCT, r2 ¼ .0097 and r2 ¼ .0121,
respectively. MM patients with ISS I (n ¼ 12) had signiﬁcant
longer OS but not PFS after ASCTcomparedwithMMpatients, g/L s-LD Above Normal s-Hb, g/dL Initial Therapy cPC%
- 13.4 Cy-Dex .001953
No 11.6 Cy-Dex .000015
No 11.5 Cy-Dex .000415
No 12.5 Cy-Dex .000083
Yes 9.7 Cy-Dex .000049
No 11.7 VAD .000779
Yes 8.1 VAD .000236
No 10.8 VAD .000050
Yes 9.1 VAD .000063
Yes 9.2 VAD .000022
- 10 Cy-Dex .002392
No 13.1 VAD .000069
Yes 7.3 VAD .000275
Yes 9.9 VAD .000631
No 10 VAD .000122
No 8.2 VAD .000791
No 12.1 VAD .000030
No 12.2 VAD .000218
No 13.5 VAD .005969
No 9.1 VAD .000236
Yes 8.8 VAD .000158
No 9.7 VAD .000094
- 10.1 VAD .000080
No 12.2 VAD .000043
erum (s)-b2-microglobulin; s-Alb, s-albumin; LD, s-lactate dehydrogenase;
Figure 1. CD34þCD133þVEGFR2þ EPC can be identiﬁed within ALDHhi population in stem cell grafts from NHL and MM patients. (A) Flow cytometry analysis of EPC in
representative stem cell grafts from NHL and MM patients (ID 10, 39, 12, and 22). FSC/SSC gating was used to identify lymphocytes and monocytes, followed by gating
on ALDHhi cells in order to deﬁne cells with stem or progenitor characteristics. EPC were subsequent deﬁned as triple positive CD34þVEGFR2þCD133þ cells (red
arrow). (B) Back-gating analysis of VEGFR2þCD133þcells shows that the majority of double positive VEGFR2þCD133þ fall within CD34 and ALDH gates. Represen-
tative sample from a MM patient (MM ID 07). (C) Bar chart illustrating distribution of EPC as percentage of CD34þ cells in stem cell grafts from patients treated with
ASCT. NHL (white bars) and MM (grey bars).
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Table 2
Clinical and Flow Cytometry Data from MM Patients with Percent EPC







Age 56.09 53.21 .18
PC (%) 27.75 34.50 .68
s-b2-M (mg/L) 2.79 5.61 .09
s-Alb (g/L) 37.05 37.23 .95
s-Hb (g/L) 10.55 10.60 .95
SR (mm/h) 50.67 68.75 .22
MFI CD133 2637 3718 .10
MFI VEGFR2 140.5 213.3 .09
CD34  106/kg 4.15 5.46 .26
SR indicates erythrocyte sedimentation rate; MFI, median ﬂuorescence
intensity.
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found no differences in EPC percentage and EPC cells per
kilogram between the ISS I and II and III subgroups
(Supplemental Figure 2A,B). In summary, the percentage of
EPC in stem cell grafts was correlated with s-b2-micro-
glubulin levels at baseline in the MM cohort but not with
other relevant clinical prognostic parameters.
We also enumerated the number of cPC in the graft to
investigate a potential correlation between EPC and cPC.
Gating strategy is outlined in Supplemental Figure 3A. cPC
percentage indicates clonal cells as a percentage of cells
within a live lymphocyte-monocyte gate. We found highly
variable frequency of cPC in the MM graft, ranging from
.000015% to .005969% of live cells within lymphocyte-
monocyte gate (Table 1). There were no signiﬁcant correla-
tion between EPC and cPC (P¼ .82, r2¼ .0023) (Supplemental
Figure 3B). MM patients with lower than cohort median of
cPC had trend towards better OS, PFS, and TNT (P¼ .0056, P¼
.084, P ¼ .098, respectively) compared with MM patients
with higher than cohortmedian of cPC, although this was not
statistical signiﬁcant in this relatively small cohort
(Supplemental Figure 4A-C). EPC was still an independent
negative prognostic indicator for PFS in multivariate analysis
when cPC was included (hazard ratio, 3.44; P ¼ .027; 95%
conﬁdence interval, 1.149 to 10.294).Figure 2. The absolute number of EPC in stem cell grafts stratiﬁes OS in MM
patients after high-dose chemotherapy with ASCT. (A) Bar chart illustrating the
estimated number of EPC infused to MM patients together with autologous
CD34þ stem cells during ASCT (n ¼ 24). EPC cells per kilogramwas deﬁned as a
ratio of measured percentage EPC of CD34þ cells as determined by ﬂow
cytometry analysis, divided by the total number of stem cells reinfused (CD34þ
cells  106/kg). MM patients were divided into two groups depending on
whether the number of EPC cells per kilogramwas above or below the median
value for the cohort. (B) Progression-free survival after ASCT in MM patients
with higher or lower than cohort median EPC cells per kilogramwas compared
with Kaplan-Meyer plot with log-rank test and found to be signiﬁcantly lower
in the group with EPC cells per kilogram higher than cohort median. (C) MM
patient OS after ASCT was compared with Kaplan-Meyer plot with log-rank
test and found to be signiﬁcant lower in MM patients with EPC cells per
kilogram higher than cohort median.DISCUSSION
Aberrant angiogenesis is one of the important hallmarks
in the multistep pathogenesis of MM disease progression
[30]. A central part in the complex process of malignant
angiogenesis is recruitment of VEGFR2þ EPC and VEGFR1þ
hematopoietic precursor cells from bone marrow [20].
However, the exact role of EPC in MM disease progression
and clinical outcome is not yet clearly understood. In the
present study, we determined the levels of EPC in PBSC
autograft samples and demonstrated that MM patients with
a high load of EPC in grafts had adverse PFS and OS after
ASCT. Of note, EPC cells per kilogram was a signiﬁcant in-
dependent negative prognostic indicator of PFS also in
multivariate analysis.
We demonstrated that EPC could be detected in autolo-
gous stem cell grafts from NHL and MM patients at variable
frequencies. However, we found no differences in EPC fre-
quencies between NHL and MM patient samples, although
stem cells grafts were mobilized with different protocols in
the 2 cohorts. This is in line with previous work showing that
there was no signiﬁcant difference in EPC levels between
MM and NHL after mobilization to peripheral blood bycyclophosphamide and granulocyte colonyestimulating
factor [31]. Unlike for MM, we could not observe any trends
towards worse outcome in NHL patients with high levels of
EPC. Accordingly, the role of angiogenesis in diffuse large B
cell lymphoma measured by microvessel density has shown
different results in regard to clinical outcome [32,33]. MM
cells grow and expand almost exclusively in the bone
marrow [34], and both osteoblastic and vascular niches can
support the proliferation of MM cells [35]. This emphasizes
Table 3
Results of Cox Regression Analysis Summarizing Signiﬁcant Independent
Prognostic Factors
Factor Hazard Ratio 95% CI P Value
EPC (cells/kg)
Low 1
High 3.44 1.15-10.29 .03
Induction chemotherapy
CR/VGPR 1
PR/SD 7.90 1.71-36.40 .008
Response after ASCT
CR/VGPR 1
PR/SD 3.75 1.24-11.29 .02
CI indicates conﬁdence interval; EPC, endothelial progenitor cells; CR,
complete response; VGPR, very good partial response; PR, partial response;
SD, stable disease; ASCT, autologous stem cell transplantation.
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ment of MM. Patients with relapsed or refractory MM,
including patients after ASCT, have signiﬁcantly improved OS
after treatment with lenalidomide [36]. Maintenance ther-
apy with lenalidomide after ASCT increases PFS [37] and OS
[38]. Lenalidomide has diverse mechanisms of action and
affects angiogenesis, immune cells, and tumor cells, although
the relative impact in different cell types is still unclear
[39,40]. However, as VEGFR2 on MM endothelial cells can be
targeted by lenalidomide resulting in impaired VEGFR2 and
ERK signaling, which is involved in migration and tubular-
like formation of endothelial cells [41], it would be of inter-
est to study whether levels of EPC in PBSC grafts could
predict response to lenalidomide and other antiangiogenic
therapies in MM. Furthermore, it has previously been
demonstrated that functional inactivation of VEGFR2 by the
monoclonal antibody anti-VEGFR2 (DC101) stopped ongoing
angiogenesis and tumor cell invasion [42].
Recently, a phase 3 trial with monoclonal antibody
VEGFR2 antagonist demonstrated clinical efﬁcacy with
improved OS in patients with advanced gastric cancer [43].
However, the results of a phase 3 trial in breast cancer pa-
tients have been disappointing [44]. Therefore, a clinical trial
investigating the incorporation of a monoclonal antibodyFigure 3. Positive correlation between s-b2-microglobulin and the percentage
of EPC in stem cell grafts from MM patients. Scatter plot of EPC as percentage
of CD34þ cells in stem cell grafts as determined by ﬂow cytometry versus s-b2-
microglobulin (mg/L) in MM patients at onset of treatment (n ¼ 23). Associ-
ation between variables was evaluated by Pearson R2.against VEGFR2 in combination with lenalidomide as an
augmented maintenance in patients with high load of EPC in
stem cell grafts would be of interest.
Of importance, we found a correlation between EPC in
stem cell grafts and s-b2-microglobulin. In MM, b2-
microglobulin is an important prognostic factor [45-47].
The association between the levels of EPC in stem cell grafts
and b2-microglobulin in peripheral blood at time of diag-
nosis are concordant with previous studies in MM, which
have reported a correlation between b2-microglobulin and
circulating endothelial cells [48] or circulating EPC [49]. The
association between b2-microglobulin and EPC highlights
the unsolved question whether levels of EPC in stem cell
grafts has a direct effect on relapse or purely acts as a sur-
rogate marker. The correlation between b2-microglobulin
before treatment and EPC in the graft could indicate that
MM patients with high tumor load at baseline mobilize more
EPC together with PBSC. The presence of cPC cells has been
shown to be associated with adverse outcome in MM after
ASCT [50,51]. A possible mechanism for EPC mobilization
could be presence of cPC. However, we found no correlation
between EPC and cPC in this MM cohort. Previously, purging
of stem cell graft by CD34 selection has no beneﬁcial impact
on long-term outcome in MM [52,53]. Nevertheless, actively
purging of EPC in stem cell grafts would be an interesting
strategy in future protocols.
In the present study, we deﬁned EPC as progenitor cells
with high intracellular ALDH expression combined with the
phenotypic surface markers CD34, CD133, and VEGFR2.Figure 4. ISS stratiﬁes OS in MM patients after ASCT. OS (A) and PFS (B) for
patients MM patients after ASCT according to ISS I (n ¼ 12) compared with
ISS II or III (n ¼ 11). Kaplan-Meyer plot with log-rank test. Signiﬁcance level of
P < .05.
E.S. Blix et al. / Biol Blood Marrow Transplant 21 (2015) 840e847846Although the properties of EPC to differentiate into mature
endothelial cells in vitro and to contribute to vessel for-
mation after transplantation was described more than a
decade ago [16], no consensus has been reached regarding a
uniform deﬁnition of EPC. EPC characterized as
CD34þCD133þVEGFR2þ has previously been identiﬁed in
NHL and MM [31], non-small cell lung cancer [54,55],
myeloﬁbrosis with myeloid metaplasia [56], and glioma
[57]. However, whether CD34þVEGFR2þCD133þ cells have
angiogenic or hematopoietic capacities is controversial [58].
These markers are also demonstrated to be expressed on
hematopoietic stem and progenitor cells, making it difﬁcult
to distinguish between endothelial and hematopoietic pro-
genitors [59,60]. Furthermore, ALDHhiCD133þ cells have
ability of multilineage reconstitution and possessed long-
term repopulating ability in secondary murine recipients
[61]. Therefore, high ALDH activity is a functional marker of
both hematopoietic and nonhematopoietic bone marrow
derived progenitor cells [62]. Recently, EPC has been char-
acterized solely as ALDHhi or as CD34þCD133þ cells [63].
Although the present study included a limited number of
MM patients, we found a signiﬁcant correlation between
increased levels of ALDHhiCD34þVEGFR2þCD133þ EPC in
stem cell grafts and adverse clinical outcome after ASCT. Of
note, the actual number of EPC infused was shown to be an
independent risk factor. Although this is a retrospective
study and the results have to be conﬁrmed by prospective
studies with a predeﬁned plan for analyses in MM patient
cohorts treated with novel agents such as thalidomide,
lenalidomide, and bortezomib, the signiﬁcant adverse
outcome in a limited patient cohort indicates an evident
difference caused by EPC. We conclude that further studies
are warranted to conﬁrm whether the EPCs in the stem cells
grafts facilitate relapse by direct action or serve as a surro-
gate marker for outcome.ACKNOWLEDGMENTS
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